Apomorphine for ED:
A Clinically Honest Look

Apomorphine is NOT FDA-approved in the United States for erectile dysfunction. It is approved and marketed as Uprima for ED in the UK and EU, where it reached clinical practice in the early 2000s. In the US, physicians prescribe it off-label using compounded formulations — primarily for men who cannot take PDE5 inhibitors (sildenafil, tadalafil) because of nitrate medication use or other contraindications. Understanding this status is the right starting point for evaluating whether apomorphine makes sense for you.

This post is part of our guide to novel ED therapies beyond PDE5 inhibitors. If you're looking for a broader overview of what these three therapies are and who they're for, start there.

How Apomorphine Works: Dopaminergic Central Mechanism

Apomorphine is a dopamine D1/D2 receptor agonist. It acts centrally — in the brain — rather than peripherally on blood vessels. By stimulating dopamine receptors in brain regions involved in sexual function (particularly the paraventricular nucleus of the hypothalamus), apomorphine appears to initiate and facilitate the erection reflex through a neurological pathway that is distinct from the nitric oxide/cGMP pathway used by PDE5 inhibitors.

It is taken as a sublingual tablet — placed under the tongue where it dissolves and absorbs rapidly into the bloodstream. The sublingual route bypasses first-pass hepatic metabolism, allowing faster onset than an oral tablet swallowed whole. Onset of effect is typically within 20–30 minutes of administration.

Because apomorphine's mechanism does not involve nitric oxide or cGMP signaling, it does not have the dangerous interaction with nitrate medications that makes PDE5 inhibitors contraindicated for men on nitrates. This is the primary clinical rationale for its use: men on nitroglycerin or other nitrate drugs for heart conditions who cannot safely take sildenafil or tadalafil may be candidates for apomorphine instead.

Clinical Evidence: How It Compares to Sildenafil

The most cited head-to-head comparison comes from Heaton et al. (2002), which compared apomorphine SL to sildenafil directly. The results were clear: apomorphine showed approximately a 55% response rate versus approximately 74% for sildenafil. Apomorphine is meaningfully less effective than sildenafil as a general ED treatment.

This is not a reason to dismiss apomorphine — it's a reason to understand exactly when it belongs in the clinical conversation. A 55% response rate is still a majority of patients. And for men who cannot take sildenafil at all, a 55% response rate from a therapy they can safely use is far better than a 0% response rate from a therapy that's contraindicated for them.

Apomorphine also has a different side effect profile than PDE5 inhibitors. It does not cause the headache and flushing from vasodilation, and it is not associated with the visual side effects occasionally seen with sildenafil. Instead, its side effects are gastrointestinal and neurological — primarily nausea, which can be significant.

Syncope Risk: A Dedicated Safety Warning

The syncope risk associated with apomorphine is dose-dependent and most pronounced at treatment initiation. In the Uprima European trials, the incidence of clinically significant syncope was low but not negligible — sufficient to require a labeled warning and to mandate that first doses be administered in a clinical setting in some protocols.

The mechanism is understood to involve dopamine-mediated vasodilation and the Bezold-Jarisch reflex. In practical terms: apomorphine can cause a sudden drop in heart rate and blood pressure in susceptible individuals. For most men this does not occur, but the risk warrants disclosure, initial low-dose titration, and awareness of the warning signs (lightheadedness, sweating, tunnel vision).

At Revive, we address this through careful patient selection, starting at the lowest effective dose, and ensuring patients understand what to do if they experience prodromal symptoms. Men with significant cardiovascular disease, hypotension, or a history of fainting receive additional evaluation before we proceed.

Who Is Apomorphine Best For?

Apomorphine occupies a specific niche in the ED treatment landscape:

• Men on nitrate medications: The primary indication. Men taking nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, or nitrate-containing products for angina or heart failure who cannot safely use PDE5 inhibitors. Apomorphine does not interact dangerously with nitrates.
• Men with PDE5 contraindications: Other cardiovascular or medication reasons that preclude PDE5 inhibitor use.
• Adjunct therapy: In some patients, apomorphine may be useful as part of a combination approach where PDE5 inhibitors provide insufficient response alone.

Apomorphine is not a first-line treatment for men who can safely and effectively use PDE5 inhibitors. Its lower response rate and syncope risk make it second-line in the general population. For a complete overview of all ED and PE medication options, visit our ED & PE Medication Guide.

Other Side Effects

• Nausea and vomiting: The most common side effects, reported in 15–30% of users. Nausea is typically dose-dependent and may diminish with repeated use as tolerance develops.
• Dizziness: Related to the vasodilatory and CNS effects of dopamine agonism.
• Somnolence: Mild drowsiness in some users, consistent with dopaminergic CNS activity.
• Headache: Reported less commonly than with PDE5 inhibitors.

Cost & Insurance Coverage

Because apomorphine is not FDA-approved for ED in the US and is prescribed off-label as a compounded formulation, it is not covered by insurance.

The Bottom Line

Apomorphine is less effective than sildenafil for general ED, has a meaningful syncope risk at initiation, and is not FDA-approved for this use in the United States. These are not reasons to categorically dismiss it — they are the precise terms under which it should be considered. For men who cannot take PDE5 inhibitors due to nitrate use or other cardiovascular contraindications, apomorphine represents a real, clinically supported alternative with a 55% response rate and a different mechanistic pathway.

For more context on how apomorphine fits alongside PT-141 and oxytocin as part of a broader off-label toolkit, read our hub article: Novel ED Therapies Beyond Viagra.

Frequently Asked Questions